Trials / Completed
CompletedNCT05291325
Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy
Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy: a Multicenter, Randomized, Controlled Clinical Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,607 (actual)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The clinical purpose of this study was to investigate whether the adjuvant application of linaclotide in bowel preparation for colonoscopy could improve the quality of bowel preparation or reduce the dosage of laxatives.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3L PEG + Linaclotide | Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy. |
| DRUG | 3L PEG | Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy. |
| DRUG | 2L PEG + Linaclotide | Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy. |
Timeline
- Start date
- 2022-05-25
- Primary completion
- 2023-08-30
- Completion
- 2024-04-28
- First posted
- 2022-03-22
- Last updated
- 2024-06-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05291325. Inclusion in this directory is not an endorsement.